Ocean Biomedical, Inc.

Ocean Biomedical, Inc. (Nasdaq: OCEA) is a biopharmaceutical company that entered the public markets through a merger with Aesther Healthcare Acquisition Corp., a blank-check vehicle sponsored by Aesther Healthcare Partners that completed its IPO in 2021. Focused on the healthcare and life sciences sector, Ocean Biomedical is developing treatments targeting pulmonary fibrosis, oncology, and infectious diseases including malaria, with research rooted in work originating from Brown University. The April 2022 quarterly filing was submitted while the proposed de-SPAC merger remained pending, ahead of the transaction's close in February 2023, after which the combined company began trading on Nasdaq under the ticker OCEA. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on Ocean Biomedical and every active SPAC transaction.